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Abstract Mutacins are bactericidal substances of proteinaceous 
nature produced by Streptococcus mutans. Lantibiotics are 
antibacterial substances containing post-translationally modified 
amino acids such as lanthionine. Mutacin B-Ny266 was purified 
from the cell pellet of S. mutans strain Ny266 by ethanol 
extraction at pH 2.0 followed by reversed-phase chromatography 
(Sep-Pak® cartridge) and by HPLC on a C]8 column. The mean 
purification factor was 3240 ± 81 and the mean yield was 
1.0 ± 0.1%. Molecular mass of mutacin B-Ny266 as determined 
by mass spectroscopy is 2270.29 ±0.21 Da. The amino acid 
sequence of the purified active fraction was obtained by Edman 
degradation after treatment with alkaline ethanethiol. Twenty-
one amino acids were detected in this analysis. Mutacin B-Ny266 
belongs to the type A lantibiotics. The proposed sequence is: F-
K-A-W-U-F-A-Abu-P-G-A-A-K-O-G-A-F-N-U-Y-A. 
The molecule differs from that of epidermin/staphylococcin 1580 
and gallidermin at positions 1, 2, 4, 5 and 6. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Bacteriocins produced by Gram-positive bacteria can be 
defined as inhibitory substances having a bactericidal mode 
of action and an essential protein moiety [1]. Bacteriocins 
produced by Streptococcus mutans were termed mutacins by 
Hamada and Ooshima [2]. Although there are many reports 
which show that S. mutans produces inhibitory substances, 
only a few such inhibitors have been isolated and character-
ized as mutacins [3-13]. The well-studied mutacins include: 
RM-10 [5], C3603 [13], JH 1000 [7], GS-5 [12], MT 3791 
and MT 6223 [6,9], mutacin-b [4], mutalipocins [8] and J-T8 
[3,10,11]. 
We previously published a preliminary classification of mu-
tacins [14], but a definitive classification will have to await the 
complete chemical characterization of these substances. 
Among the known mutacins, only T8, which belongs to group 
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Abbreviations: Abu, 2-aminobutyric acid; ATCC, American Type 
Culture Collection; AU, arbitrary units; BM-Lan, P-methyllanthio-
nine; BMSEC, p-methyl-S-ethylcysteine; dhA or U, 2,3-didehydro-
alanine; dhB or 0,(2)-2,3-didehydrobutyrine; DSER, PTH-
dithiothreitol adduct of dhA; HPLC, high-pressure liquid chroma-
tography; Lan, lanthionine; OP A, o-phthaldialdehyde; PTH, phen-
ylthiohydantoin; RP-HPLC, reversed-phase high-pressure liquid 
chromatography; SEC, S-ethylcysteine; TFA, trifluoroacetic acid; 
TSAYE, trypticase soy agar yeast extract 
J [14], was identified as a lantibiotic and its first eight N-
terminal amino acid residues were determined by Novak et 
al. [10]. Lantibiotics are defined as bacterium-derived riboso-
mally synthesized lanthionine-containing peptides with antibi-
otic activity [1,15,16]. They generally contain unsaturated 
amino acids like 2,3-didehydroalanine, and (2)-2,3-didehydro-
butyrine. The lantibiotics are divided into two types [1,15-17]. 
Type A comprises screw-shaped, amphipathic molecules with 
molecular masses between 2151 and 4635 Da and with 2-7 net 
positive charges. Type B consists of more globular molecules 
with molecular masses between 1825 and 2042 Da and with 
either no net charge or a net negative charge. 
In this paper, we present the results of the purification and 
the determination of the first complete sequence of a lanti-
biotic produced by S. mutans. Mutacin B-Ny266 was previ-
ously shown to inhibit 98% of the S. mutans strains tested [14] 
and all tested Gram-positive bacteria including Listeria 
monocytogenes, Clostridium sporogenes, Mycobacterium phlei, 
Staphylococcus aureus, Enterococcus faecalis and Bacillus sub-
tilis [18]. In the present work, the mature peptide was purified 
to homogeneity and its amino acid sequence was determined 
as: F -K-A-W-U-F-A-Abu-P-G-A-A-K-O-G-A-F-N-
U-Y-A (underlined residues participate in lanthionine or p-
methyllanthionine bridges; see Section 3). 
2. Material and methods 
2.1. Mutacin production 
Strain Ny266 of Streptococcus mutans was obtained from J.J. van 
der Hoeven (Dept. of Preventive Dentistry, University of Nijmegen, 
Nijmegen, The Netherlands). An overnight preculture in M17 broth 
(BDH Inc., St-Laurent, QC, Canada) was used to inoculate (1%) 1 1 
of M17 broth in 2-1 flasks. The cultures were incubated at 37°C under 
aerobic conditions in a standing incubator for 24 h. 
2.2. Determination of inhibitory activity 
Trypticase Soy Agar (Difco Laboratories, Detroit, MI) plates en-
riched with 0.3% yeast extract were overlaid with 5 ml of melted 
TSAYE containing a standardized suspension (0.2 ml of an exponen-
tially growing culture at an optical density of 0.1 at 600 nm) of Micro-
coccus luteus ATCC 272 (ATCC, Rockville, MD). In order to assess 
the activity of mutacin samples, 2-fold dilutions were prepared in 
0.11% TFA (Sigma Chemical Co., St. Louis, MO) and 5 ul of each 
dilution deposited on top of the indicator plates. Mutacm activity was 
expressed in arbitrary units, which correspond to the reciprocal of the 
last dilution giving a clear inhibition zone against M. luteus after 24 h 
of incubation at 37°C under aerobic conditions [19]. 
The specific activity of each preparation was expressed in AU/mg 
protein. Protein concentrations were determined using the Bio-Rad 
DC protein assay (Bio-Rad, Mississauga, Ontario, Canada). 
2.3. Mutacin extraction and purification 
One liter of a 24-h culture of S. mutans Ny266 was centrifuged at 
lOOOOXg for 15 min and the mutacin was extracted from the cell 
pellet with a mixture of 20 ml of HC1 (20 mM) and 80 ml of ethanol 
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(70%) at pH 2.0 (adjusted with HC1). The suspensions were heated at 
70°C for 40 min, cooled on ice, and centrifuged at lOOOOXg for 15 
min. This method was adapted from an extraction technique described 
by Hurst [20]. The supernatants were evaporated with a rotary evap-
orator at 37°C and the concentrates were applied to Cig Sep-Pak® 
cartridges (Waters Corporation, Milford, MA) and eluted with a dis-
continuous gradient of acetonitrile (12%, 18%, 24%>, 30%, 33%> and 
60% acetonitrile) were then concentrated with a rotary evaporator and 
dried in a Speed-Vac® concentrator (Model SC110A, Savant Instru-
ments Inc., Farmingdale, NY). The fractions were re-solubilized in 
0.11% TFA. They were further purified by RP-HPLC using an ana-
lytical Cis column (Vitropack Lichrosorb RP 18, 5 urn; LKB, Phar-
macia Biotech, Uppsala, Sweden). 
The chromatography was performed on an LKB system (Pharma-
cia) equipped with two pumps (model 2150), a controller (model 
2152), a variable wavelength monitor (model 2151), a Rheodyne 
M7010 sample injection valve with a 20 u.1 loop, and a Hewlett-Pack-
ard 3396 integrator. Elution was carried out with solvent (A): 0.11% 
TFA and solvent (B): 60%> acetonitrile in 0.1% TFA. The peptides 
were eluted with a linear gradient of acetonitrile over 44 min at a flow 
rate of 1 ml/min and detected at 220 nm. The upper half of the peak 
showing activity (HPLC I) was concentrated in a Speed-Vac® and re-
injected under the same conditions to yield fraction HPLC II and 
finally the pooled sample consisting of the upper third fraction of 
this peak from eight different batches was injected under the same 
conditions to yield a unique peak (HPLC III) which was used for 
chemical analyses. 
2.4. Polarity calculation 
The polarity was calculated from the percentage of acetonitrile at 
which the substance eluted according to the formula given by Snyder 
[21]. 
2.5. Purity assessment 
The purity of mutacin preparations was assessed by capillary elec-
trophoresis. The samples were injected into a 44-cm capillary (2023 
Fused silica capillary, 50 urn ID) by hydrodynamic injection on a 
capillary electrophoresis system (Thermo SP Separation Products, 
Toronto, Ontario, Canada). The separation was carried out at 25 
kV in sodium phosphate buffer (pH 2.5) and 15% (v/v) acetonitrile, 
at 30°C. The detection was at 200 nm. 
2.6. Molecular mass determination 
Molecular mass was determined for fraction HPLC III by electro-
spray mass spectroscopy on a VG/Fisons Quatro II electrospray triple 
quadrupole mass spectrometer (Fison Instruments, Manchester, UK) 
at the Department of Chemistry, University of Waterloo, Waterloo, 
Ontario, Canada. 
2.7. Amino acid analysis 
Purified mutacin B-Ny266 (fraction HPLC III) was submitted to 
acid hydrolysis (6 N HC1, 110°C, 21 h) and o-phthaldialdehyde deri-
vatization according to Sahl et al. [22]. The amino acids were analyzed 
by RP-HPLC chromatography on a Waters HPLC system (Waters 
Chromatography Division, Milford, MA) consisting of a Waters Ra-
dial-Pak Cig 4-|xm column (8 mmXlO cm) at 40°C, two pumps 
(Waters model 510) and an automatic injector (Waters Model 715). 
The OPA amino acid derivatives were detected at 425 nm (excitation 
wavelength 338 nm) on a fluorescence detector (Waters, Model 420). 
The sum of the Lan and/or BM-Lan residues was determined using 
D,L-lanthionine (Sigma) as a standard. The number of amino acid 
residues was calculated from the molar ratio relative to Ala and Asx. 
Table 1 
Mean yield of mutacin B-Ny266 for each purification step" 
MUTACIN B-Ny266 
Purification 
Sep-Pak® 
HPLC I 
HPLC II 
HPLC III 
Total 
step Purification factor 
36 ±27 
5± 3 
3± 1 
6 
3240 ±81 
Yield (%) 
31 ±22 
22 ± 2 
49 ±22 
31 
1.0± 0.1 
F - K - A - W - U - F - A - A b u - P - G - A - A - K - O - G - A - F - N - A - Y - A 
I s I I \ 
" S NH 
\ / 
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EPIDERM1N 
(STAPHYLOCOCCIN 1580) 
I * I | S 1 
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"Values presented are the mean ± SD of eight purifications, except for 
the third HPLC chromatography, which was performed only once. 
I - A - A - K - F - L - A - A b u - P - G - A - A - K - O - G - A - F - N - A - Y - A 
L s ^ I \ 
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Fig. 1. Comparison of the proposed structure of mutacin B-Ny266 
with those of epidermin (staphylococcin 1580) and gallidermin. 
2.8. Sequence determination 
Automatic Edman degradation was performed on a Pulsed Liquid 
Protein sequencer (Applied Biosystems model 473, Foster City, CA) 
after ethanethiol treatment as described by Meyer et al. [23] to permit 
sequencing of lantibiotics. The results were interpreted according to 
Meyer et al. [23]. 
2.9. Protein sequence accession number 
The sequence of mutacin B-Ny266 has been deposited in the 
SWISS-PROT protein sequence database under accession number 
P80666. 
3. Results 
The purification procedure was repeated 8 times. The mean 
cell yield of the cultures in M17 broth was 0.79 ±0.04 g 
(mean ± SD) of cell dry weight/1. The specific activity of the 
cell pellet extracts was 115 ±43 AU/mg of protein. The spe-
cific activity recovered from the supernatants was 22 ± 3 AU/ 
mg of protein. Therefore, only cell pellet extracts were further 
purified. 
The mean values obtained from the eight runs for the pu-
rification and yield for each step are presented in Table 1. On 
the whole, mutacin B-Ny266 was purified 3240 ± 81-fold with 
a yield of 1.0 ±0.1%, which corresponds to 3.4 ±0.3 (ig/1 of 
culture. The substance was found to be more than 99.9%) pure 
by capillary electrophoresis. As mutacin B-Ny266 elutes at 
33.3% acetonitrile during RP-HPLC, its polarity was calcu-
lated to be 8.067. 
The electrospray mass spectroscopy analysis yielded a mo-
lecular mass of 2270.29 ± 0.21 Da for the purified mature pep-
tide. 
Taking into account the limits of amino acid analysis after 
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Table 2 
Amino acid composition of mutacin B-Ny266 
Number of residues per molecule Amino acid 
(one letter code) Amino acid analysisa(probable number of residues) Edman degradation Calculated molecular weight(Da) 
Ala (A) 
Asx (N, D) 
Gly (G) 
Lys (K) 
Phe (F) 
Tyr(Y) 
Lan/BM-Lanb 
dhA (U) 
dhB (O) 
Pro (P) 
Trp (W) 
1.2(1) 
0.8 (1) 
1.5 (1-2) 
2.5 (2-3) 
2.9 (3) 
0.7 (1) 
2.7 (3) 
0C 
0C 
NQd 
0C 
1 
1(N) 
2 
2 
3 
1 
3 (2 Lan + 1 BM-Lan) 
2 
1 
1 
1 
+ 1H (N-terminal) 
71.08 
114.10 
114.10 
256.35 
441.53 
163.18 
530.65 
138.13 
83.09 
97.12 
186.21 
2195.54 
1.01 
2196.55 
aThe number of amino acid residues was calculated from the molar ratio relative to Ala and Asx after OPA derivatization. 
bLan = lanthionine; BM-Lan = fj-methyllanthionine. 
cdhA, dhB and Trp are acid labile and are not detected by the method used. 
dNQ, not quantified by OPA derivatization. 
acid hydrolysis and OPA derivatization, the amino acid con-
tent as determined by acid hydrolysis and Edman degradation 
are consistent (Table 2). Forty percent are modified amino 
acid residues. 
Edman degradation after treatment with alkaline ethane-
thiol revealed 21 residues with the following sequence: 
F 1 - K 2 - ( S E C + 3 D S E R ) - W 4 - S E C 5 - F 6 - ( S E C + 7 D S E R ) -
B M S E C 8 - P 9 - G 1 0 - ( S E C + n D S E R ) - A 1 2 - K 1 3 -
BMSEC 1 4 -G 1 5 -SEC 1 6 -F 1 7 -N 1 8 -SEC 1 9 -Y 2 0 -SEC 2 1 
The sample was sequenced with an initial yield of 1060 
pmol and a repetitive yield of 87.2%. The level of confidence 
was higher than 99%. 
4. Discussion 
Mutacins have always been difficult to obtain from liquid 
cultures [2,18,24-26]. Novak et al. [10] recently obtained good 
production of mutacin J-T8 in a chemically defined medium 
enriched with yeast extract and trypticase soy broth. We ob-
tained a good production of mutacin B-Ny266 in the commer-
cially available medium Ml7 (BDH). Furthermore, we de-
scribe a simple technique permitting the extraction of the 
mutacin activity from cell pellets and we present, for the first 
time, the complete amino acid sequence of a mutacin. 
Although the specific activity recovered from cell pellets is 
higher than that recovered from supernatants of bacterial cul-
tures, the total amount of activity in the supernatants was 
calculated to be, on average, six times that of the cell extracts. 
Actually, we can recover 40% of this activity, but with a lower 
purity than from the cell extract (data not shown). We are 
presently working on a more efficient method to purify muta-
cin B-Ny266 from these supernatants, which would improve 
the total culture yields. Although the method of extraction 
presented permits the recovery of the active substance from 
cells, we observed a high variability from one extraction to 
another. Thus, the extraction and purification procedures 
have to be improved in order to increase the yield and reduce 
this variability. The procedure nevertheless permitted the pu-
rification of the lantibiotic B-Ny266 using only hydrophobic-
ity chromatography. No impurities interfered with the deter-
mination of molecular mass and the amino acid sequencing. 
Furthermore, capillary electrophoresis indicated that the sub-
stance was more than 99.9% pure. 
At our first sequencing attempt, Edman degradation was 
blocked at the first dhA (residue 5), the Trp4 was barely de-
tectable, and a blank was obtained in the third position (pre-
liminary results not shown). The ethanethiol treatment de-
scribed by Meyer et al. [23] permitted the complete (residue 
22 excepted) sequencing of our molecule. These results thus 
confirm the conclusions of Meyer et al. [23] on the usefulness 
of this method for the automatic sequencing of lantibiotics. 
The results obtained from amino acid analysis and Edman 
degradation are consistent (Table 2), taking into account the 
residues that could not be identified by amino acid analysis. 
Residues dhA, dhB and Trp are acid labile and are not de-
tected by acid hydrolysis and OPA derivatization [22,27], and 
Pro cannot be quantified by OPA derivatization. 
According to Meyer et al. [23], the detection of a SEC 
signal (residues 5, 16, 19 and 21) during Edman degradation 
after ethanethiol treatment indicates the presence of a dhA 
residue. 
When this SEC signal is accompanied by a DSER signal 
(residues 3, 7, 11), it indicates the presence of a lanthionine 
residue. At cycles 16, 19 and 21, the DSER signal was not 
observed. These positions would correspond to a dhA residue. 
However, the DSER signal is always very low [23]. It is pos-
sible that, as cycles 16, 19 and 21 are at the end of the se-
quence, the corresponding DSER signal is undetectable. Fur-
thermore, if we compare the molecule of B-Ny266 with closely 
similar substances such as epidermin (staphylococcin 1580) 
and gallidermin (Fig. 1), position 16-21 is occupied by a lan-
thionine. This would also be in accordance with the results of 
the amino acid analysis, in which we detected 3 Lan/BM-Lan 
(Table 2). We can thus hypothesize that these residues could 
be Lan3-7, BM-Lan8-ll and Lanl6-21. The SEC signal de-
tected at position 19 indicates a dhA in the molecule. This 
dhA could well result from breakage of a link with the S-(2-
aminovinyl)-D-cysteine residue, leaving a dhA in position 19 
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Table 3 
Comparison of the first 7 N-terminal amino acids of mutacin B-Ny266 with other known lantibiotics of group A 
Lantibiotics N-terminal sequence" Reference 
Mutacin B-Ny266 
1 2 3 4 5 6 7 
I S 1 
F - K - A - W - U - F - A This paper 
Epidermin 
Staphylococcin 1580 
Gallidermin 
Nisin A 
Nisin Z 
I - A 
I - O - A - I 
1 
A 
1 
A 
1 
- K -
- K -
—s-
- F 
i _ > 
- F 
o 
 - I - A 
L - A 
U - L - A 
c 
d 
f 
g 
Subtilin W - K - A - E - U - L - A 
Salivaricin A R - G - S - G - W - I 
Streptococcin A-FF22 G - K - N - G - V - F - K . . . J 
Lacticin 481 
Lactococcin DR 
K - G - G - S - G - V - I . 
Mutacin J-T8 N W W - Q G - V m 
Lactocin S S - T - P - V - L - A - S 
Epilancin K7 X U V L - K 0 
a Amino acids are identified by the one-letter code; U and O represent, respectively, 2,3-didehydroalanine and 2,3-didehydrobutyrine [42]. 
References: bthis work; c[33]; d[34]; e[35]; f[36]; s[27]; h[37]; '[38]; '[32]; k[39]; '[40]; m[10]; n[41]; °[42]. 
and S-(2-aminovinyl) in the terminal position (which was not 
detected in our sequence analysis). Although it was not de-
tected, this C-terminal aminovinyl-cysteinyl residue can be 
assumed from the comparison of the molecular masses ob-
tained by mass spectroscopy analysis (2270.29 ±0.21 Da) 
and the total mass obtained from the addition of all the res-
idues calculated from the amino acid sequence (2196.55 Da) 
(Table 2). The difference between the two masses (73.74 ± 0.21 
Da) agrees well with the molecular mass of a S-(2-aminovinyl) 
residue (73.12 Da). This assumption would again correspond 
to the known structures of epidermin and gallidermin (Fig. 1). 
The signals corresponding to BMSEC indicate the presence 
of an Abu or a dhB [23]. We observed these signals for res-
idues 8 and 14 during the sequencing. By analogy with the 
molecules of epidermin and gallidermin, we assigned Abu for 
residue 8 and dhB for residue 14. 
M. Mota-Meira et al.lFEBS Letters 410 (1997) 275-279 279 
If we hypothesize the same mode of post-translational mod-
ification for mutacin B-Ny266 as for other lantibiotics [16,17], 
the pro-B-Ny266 would thus have the following sequence: F -
K - S - W - S - F - C - T - P - G - C - A - K - T - G - S - F - N - S - Y - C - C . 
We are presently attempting to clone and sequence the corre-
sponding gene in order to confirm the proposed primary 
structure. 
According to the results presented, mutacin B-Ny266 differs 
from epidermin and gallidermin in positions 1, 2, 4, 5 and 6 
and could thus be regarded as type A lantibiotic (Fig. 1 and 
Table 3). It is surprising that similar lantibiotics are produced 
by different bacterial genera. Epidermin and gallidermin are 
produced by staphylococci (S. epidermis and S. gallinarum 
respectively) while mutacin B-Ny266 is produced by a strep-
tococcus (S. mutans). The Lan3-7 , which is a common struc-
ture among group A lantibiotics [1], is also present in mutacin 
B-Ny266. The Lys2 is also found in subtilin and streptococcin 
(SA-FF22). The importance of this position for the character-
istics of the molecule have so far not been studied. The se-
quence F l - K 2 - L a n 3 can be found in inverted form as F 5 -
K 4 - L a n 3 in epidermin/staphylococcin 1580 and gallidermin. 
The significance of this observation eludes us for the moment , 
but it could point toward a common origin for these three 
lantibiotics. 
Mutacin B-Ny266 possesses a dhA residue in position 5. 
This dhA5 was found to be important for the activity and 
stability of nisin [28], and for the sporicidal activity of nisin 
[29] and subtilin [30]. The possibility of a similar implication 
of the dhA5 residue in mutacin B-Ny266 activity would be 
well worth testing. Position 6 of epidermin and gallidermin 
seems to be implicated in antibacterial activity and resistance 
to trypsin [31]. While this position is occupied by I and L 
residues in epidermin and gallidermin, respectively, an F6 res-
idue is found in mutacin B-Ny266, as for streptococcin A-
FF22 [32]. Mutacin B-Ny266, epidermin, gallidermin and 
SA-FF22 must be compared with respect to their resistance 
to trypsin and their spectrum of action. 
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